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Abstract Recent studies indicate that mesenchymal stem
cells (MSC) exhibit a degree of immune privilege due to
their ability to suppress T cell mediated responses causing
tissue rejection; however, the impact of allogeneic MSC in
the setting of organ transplantation has been poorly investi-
gated so far. The aim of our study was to evaluate the eVect
of intravenous donor MSC infusion for clinical tolerance
induction in allogeneic skin graft transplantations in rats.
MSC were isolated from Wistar rats and administered in
Sprague-Dawley rats receiving Wistar skin graft with or
without cyclosporine A (CsA). Graft biopsies were per-
formed at day 10 post transplantation in all experimental
groups for histological and gene expression studies. Intra-
venous infusion with donor MSC in CsA-treated trans-
planted rats resulted in prolongation of skin allograft
survival compared to control animals. Unexpectedly, donor
MSC infusion in immunocompetent rats resulted in a faster
rejection as compared to control group. Cytokine expres-
sion analysis at the site of skin graft showed that CsA treat-
ment signiWcantly decreased pro-inXammatory cytokines
IFN- and IL-2 and reduced TNF- gene expression; how-
ever, the level of TNF- is high in MSC-treated and not
immunosuppressed rats. Results of our study in a rat tissue
transplantation model demonstrated a possible immuno-
genic role for donor (allogeneic) MSC, conWrming the need
of adequate preclinical experimentation before clinical use.
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Introduction
The introduction of modern immunosuppressive therapies
has improved the survival rates for solid organ allo-trans-
plantation in humans. However, immunosuppressive drug
toxicity and side eVects lead to late allograft loss. Thus, the
induction of a state of permanent tolerance to an allograft,
deWned as a state of unresponsiveness to donor antigens in
the absence of long-term immunosuppressive therapy, is an
elusive goal in human solid organ transplantation. Several
approaches of cellular therapy have been used in an attempt
to achieve immunological tolerance in non-human primate
and human studies [11]. Stem cell mediated tolerance was
experienced with the use of donor whole bone marrow cell
(DBMC) infusions [2, 24, 26, 35, 39]. Results of published
experiences suggest that donor bone marrow cells infusion
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outcome after transplantation [32]. Patients who show a full
chimerism after myeloablative therapy and bone marrow
(BM) transplantation for treatment of haematopoietic
malignancy will accept renal transplants and other tissue
transplants from their speciWc BM donor without require-
ment for immunosuppressive therapy [6].
Mesenchymal stem cells (MSC) are cells derived from
varying fetal and adult organs and have the capacity of self-
renewal and of diVerentiating in several tissues including
bone, cartilage, stroma, fat, muscle, and tendon [29].
Numerous in vitro studies demonstrate that MSC from vari-
ous species can suppress T-cell proliferation, in autologous
and alloreactive conditions, in response to various stimuli
with cell contact dependent and independent mechanisms
[1, 25, 31, 38].
In support of their in vivo immunosuppressive features
are the observations that allogeneic MSC may prolong skin
allograft survival in immunocompetent baboons [16], pre-
vent the rejection of allogeneic B16 mouse melanoma cells
in immunocompetent mice [7], attenuate graft versus host
disease (GvHD) in mice and humans [4, 19], and have a
role in the treatment of autoimmune disorders [40]. How-
ever, the impact of allogeneic MSC in the setting of organ
transplantation has been poorly investigated to date. A
recent work by Inoue et al. [16] on a rat organ transplant
model conWrms the MSC immunomodulatory properties in
vitro but suggests caution for their use in vivo, as MSC
injections were not eVective in prolonging heart allograft
survival inducing rejection instead of tolerance.
The immunogenicity of skin, the most antigenic tissue in
the body, is the major obstacle for the skin allograft survival,
resulting in rejection within 10–12 days without immuno-
suppressive therapy. Tolerance to skin allografts is very diY-
cult to induce except under particular conditions. Recently, it
has been demonstrated that skin allograft survival is pro-
longed by the injection of donor epidermal cells together
with bone marrow cells [28]. The potential for the use of
BM-derived MSC in prolonging skin graft survival was
reported by the study of Bartholomew et al. [3]. The authors
demonstrated that infusion of major histocompatibility
complex (MHC)-mismatched MSC into baboons had been
well tolerated and prolonged skin graft survival in vivo. Fur-
thermore, baboon MSC suppress the proliferative activity of
allogeneic peripheral blood lymphocytes (PBL) in vitro.
Based on the above-mentioned Wndings, our aim was to
evaluate the role of donor MSC in tolerance induction in a
rat model of skin transplantation. In particular, we evalu-
ated the eVects of intravenous donor MSC infusion on skin
allograft survival in an experimental model using Wistar
rats as donors and Sprague-Dawley (SD) rats as recipients;
both as a comparison with, and in addition to, the conven-
tional immunosuppressive treatment with cyclosporine A
(CsA). In addition, we evaluated whether MSC infusion
could aVect the gene expression proWle of some pro- and
anti-inXammatory cytokines that could play a role in the
modulation of the immune response for skin allograft toler-
ance or rejection.
Materials and methods
Animals
Wistar and Sprague-Dawley (CD) rats (Charles River Lab-
oratories) were used in this study. Adult male Wistar rats
weighing 300–350 g were used as skin graft and MSC
donors. Adult male Sprague-Dawley rats weighing 300–
350 g were used as skin graft recipients. For each experi-
mental arm, we used three donors and at least 20 recipients.
Rats were housed in an accredited animal facility (Istituti
Biologici-San Miniato Stabularium, Siena, Italy) and
treated under conditions approved by the Local Ethical
Committee of the University of Siena, Italy.
Study design
We performed a case–control study to assess the eVect of
intravenous administration of MSC in rats that had under-
gone skin allograft transplantation. The experimental
design (Table 1) included four arms; in each arm we per-
formed an autograft in two animals and an allograft in at
Table 1 Summary of graft rejection and survival after MSC injection
* Numbers represent mean § SD days of graft survival among the animals that rejected the graft during the 30-day observation period. Immuno-
suppression was performed with intramuscular administration of CsA at 5 mg/kg per day. MSC were infused in the tail vein with a dosage of
5.7 £ 106/kg at day 0 and 10.3 £ 106/kg at day +3
Group Donor Recipient MSC injection 
(day 0 and +3)
CsA Number of 
transplanted rats
Percent of not 
rejected grafts (%)
Percent of 
rejected grafts (%)
Graft 
survival* (days)
A Wistar Sprague-Dawley No No 13 0 100 17 § 1.8
B Wistar Sprague-Dawley No Yes 14 43 57 15 § 3.8
C Wistar Sprague-Dawley Wistar MSC Yes 14 57 43 19 § 3
D Wistar Sprague-Dawley Wistar MSC No 21 0 100 13 § 1123
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rats that received a skin transplantation only; rats of arm B
received skin transplantation and immunosuppressive ther-
apy with CsA; rats of arm C received skin transplantation,
immunosuppressive therapy, and intravenous infusion of
donor MSC; rats of arm D received skin transplantation and
intravenous donor MSC infusion. For each arm, half the
number of animals were inspected daily to evaluate skin
graft survival (days between transplantation and rejection)
and the others were sacriWced on day 10 post transplanta-
tion in order to perform two punch biopsies for histopathol-
ogy and gene expression proWle of the graft.
Skin graft placement and evaluation
Skin transplantation was performed according to the meth-
ods described by Taylor and Morris [37] with some modiW-
cations: in brief, after tiletamine–zolazepam sedation
(Zoletil 20®) (30 mg/kg i.p.), 1.5 £ 1.5 cm full-thickness
skin grafts were harvested from the donor abdominal sur-
face. After removal of the subcutaneous tissue, skin grafts
were placed on the abdomen of the recipient rat, Wxed with
simple separate stitches, and covered with a wet buVered
bandage. This procedure supports neo-vascularization and
engraftment. The graft was then protected by a zinced ban-
dage that was removed on day 7. Grafts that failed up to
this point were considered as technical failure and excluded
by the study. The graft was inspected daily until rejection
or until the end of the experiment (30 days). Grafts were
considered rejected when at least 90% of graft tissue had
disappeared or had become necrotic.
MSC administration
Sprague-Dawley rats of arm C and D received Wistar MSC
in the tail vein after completion of the skin graft procedure
(day 0) and on day 3, post transplantation. The administered
MSC dose was 5.7 £ 106/kg in 200 l of 0.9% NaCl solu-
tion at day 0 and 10.3 £ 106/kg in the same conditions at day
3. Animals of arms A and B received intravenous 0.9%
NaCl solution in the same volume and with the same timing.
CsA administration
Animals of arms B and C received intramuscular CsA
(Sandimmun®; Novartis, Novartis Farma S.p.A., Varese,
Italy) administration at a dose of 5 mg/kg per day from day
0, as previously described [5].
MSC isolation and culture expansion
Rat BM cells were collected from male Wistar rats follow-
ing the Dobson procedure [9]. BrieXy, once the femurs and
tibiae were extracted, their proximal ends were removed,
and the bones were then placed in microcentrifuge tubes
supported by plastic inserts cut from 1 ml hypodermic nee-
dle casings and brieXy centrifuged at 700g for 2 min. The
marrow pellet was re-suspended in 10 ml of Hank’s bal-
anced salts solution (HBSS, w/o calcium and magnesium;
Euroclone, Milan, Italy) + 1% fetal bovine serum (FBS,
HyClone, South Logan, Utah, USA) and washed (300g for
7 min). After the cells were passed through a 22-G needle,
they were re-suspended in culture medium (DMEM-Low
Glucose, with L-glutamine, 25 mM HEPES and pyruvate,
GIBCO™–Invitrogen, Milan, Italy, supplemented with
10% FBS), counted using a hemocytometer and seeded at
24 £ 106/75 cm2 Xask. Cells were incubated at 37°C in a
humidiWed atmosphere containing 95% air and 5% CO2.
Half of the complete medium was changed after 1 week and
thereafter the whole medium every 3–4 days. When
approximately 80% of the Xask surface was covered, the
adherent cells were incubated with 0.05% trypsin–0.02%
EDTA (Eurobio, Courtaboeuf, Cedex B, France) for 5–
10 min at 37°C, harvested, washed with HBSS and 10%
FBS, and re-suspended in complete medium (primary cul-
ture, P0). Cells were then re-seeded at 104 cells/cm2 in 100-
mm; dishes (P1): expansion of the cells was obtained with
successive cycles of trypsinization and reseeding. MSC
were identiWed and characterized according to published
studies [20, 21].
CFU-F frequency
The number of colony forming units-Wbroblasts (CFU-F)
was used as a surrogate marker for MSC progenitors
frequency: two 100-mm; dishes were seeded with
1 £ 106 total nucleated cells. After incubation for 14 days
at 37°C in 5% CO2 humidiWed atmosphere, the dishes were
rinsed with HBSS, Wxed with methanol and stained with
Giemsa: visible colonies formed by 50 or more cells [12]
were counted and reported as number of CFU-F/106 seeded
total nucleated cells (TNC).
Osteogenic and adipogenic diVerentiation of MSC
MSC (104 cells/cm2) were grown near conXuence in
25 cm2 Xasks and then incubated in osteogenic medium
(DMEM–LG with 10% FBS; 10 nM dexamethasone,
100 g/ml ascorbic acid and 10 mM -glycerophosphate
(all from Sigma, St Louis, MO, USA), or in adipogenic
medium (DMEM–LG with 10% FBS; 0.5 mM isobutyl
methylxanthine, 10 M dexamethasone, 10 g/ml insu-
lin, and 70 M indomethacin, all from Sigma, St Louis,
MO, USA). The medium was replaced every 3–4 days
and the deposition of mineral nodules or the accumula-
tion of lipid-containing vacuoles was revealed after123
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respectively.
Immunophenotyping
At the fourth or Wfth passage, the morphologically homoge-
neous population of MSC was analysed for the expression
of particular cell surface molecules using Xow cytometric
procedures: MSC recovered from Xasks by trypsin–EDTA
treatment and washed in HBSS and FBS 10% were re-sus-
pended in Xow cytometry buVer consisting of CellWASH
(0.1% sodium azide in PBS; Becton Dickinson, San Jose,
CA, USA) with 2% FBS. Aliquots (1.5 £ 105 cells/100 l)
were incubated with the following conjugated monoclonal
antibodies: CD45-CyChrome™, CD11b-FITC (in order to
quantify hemopoietic-monocytic contamination), CD90-
PE, CD106-PE, CD73-PE, CD54-FITC, CD44-FITC (BD
Pharmingen, San Diego, CA, USA). Non-speciWc Xuores-
cence and morphologic parameters of the cells were
determined by incubation of the same cell aliquot with iso-
type-matched mouse monoclonal antibodies (Becton Dickin-
son, San Diego, CA, USA). All incubations were performed
for 20 min and after incubation, cells were washed and re-
suspended in 100 l of CellWASH; 7-AAD (7-amino-acti-
nomycin D) was added in order to exclude dead cells from
the analysis. Flow cytometric acquisition was performed by
collecting 104 events on a FACSort (488 nm argon laser
equipped, Becton Dickinson, San Jose, CA, USA) instru-
ment and data were analysed on DOT-PLOT bi-parametric
diagrams using CELL QUEST software (Becton Dickin-
son, San Jose, CA, USA) on a Macintosh PC.
Histopathology
Skin graft punch biopsies (6 mm;) were performed on day
10 post transplantation in ten animals for each group and
skin samples were Wxed with formalin and stained with
haematoxylin–eosin for histological evaluation. Slides were
analysed in a blinded fashion. Two parameters, inXamma-
tory inWltrate (F) and epidermis thickness (ET), were ana-
lysed. InXammatory inWltrate were scored as follows: 0 no
inXammation, 1 focal and mild, 2 diVuse and moderate, 3
diVuse and severe. ET was calculated as the mean of Wve
thickness measures (m) of epidermis from granular to
basal layer.
RNA extraction and real-time quantitative RT-PCR
Total RNA from rat skin was isolated by using the RNeasy
midi kit (Qiagen, Germany) according to the manufac-
turer’s protocol. Five micrograms of RNA were reverse
transcribed separately using M-MLV transcriptase (Gibco
BRL) and random hexamer primers (Amersham). In order
to quantify the transcribed interleukin 2 (IL-2, M22899),
interleukin 10 (IL-10, L02926), interferon gamma (IFN-,
AF010466), transforming growth factor beta (TGF-,
AY550025), and tumor necrosis factor alpha (TNF-,
X66539) genes, we performed TaqMan RT-PCR (PE
Applied Biosystems, Foster City, CA) in ABI-PE Prism
7700 sequence detection system. VIC-labeled rodent glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) (assay-
on-demand #4308313) and FAM-labeled rattus IL-2
(assay-on-demand # Rn00587673_m1), IL-10 (assay-on-
demand #Rn00563409_m1), IFN- (assay-on-demand
#Rn00594078_m1), TGF- (assay-on-demand #Rn00
579697_m1), and TNF- (assay-on-demand # Rn01
525860_g1) TaqMan pre-developed assays (Applied Bio-
systems) were used. The threshold cycles (the PCR cycle at
which an increase in reporter Xuorescence above a baseline
signal can Wrst be detected) of each target product was
determined and set in relation to the ampliWcation plot of
the housekeeping gene, GAPDH. All experiments were run
in duplicate with 50 ng cDNA, and the same thermal
cycling parameters were used. Fold change was calculated
relative to control skin cycle threshold (Ct). The Ct value is
deWned as the number of PCR cycles required for the Xuo-
rescence signal to exceed the detection threshold value.
With the PCR eYciency of 100%, Ct values of the sam-
ples were determined by subtracting the average of the Ct
values of the target genes from the average of the Ct values
of the GAPDH gene. The relative gene expression levels
were determined by subtracting the average Ct value of
the target from the average Ct value of the calibrator. The
amount of target (expressed as fold change), normalised to
an endogenous reference and relative to a calibrator, was
given by 2¡Ct.
Statistical analysis
The survival allograft time in the groups was evaluated by
the Kaplan–Meier method and the eYcacy of treatment by
the Logrank test. DiVerences in gene expression among
diVerent animal groups were tested by using the non-para-
metric Kruskal–Wallis test. DiVerences in gene expression
between two groups were tested by using the non-paramet-
ric Mann–Whitney test. A P value of less than 0.05 was
considered statistically signiWcant.
Results
rMSC characterisation
Rat BM-derived MSC were successfully culture-expanded.
Cells were particularly heterogeneous until the fourth–Wfth
passage in culture and also comprised numerous lipid123
Arch Dermatol Res (2008) 300:115–124 119vacuoles. Haematopoietic cells were lost during the medium
changes as shown by Xow cytometric analysis. Primary
culture cells were trypsinised and plated, reaching a cellu-
lar expansion up to a mean 109 factor in 3 months (Fig. 1a).
After the Wfth passage, the cells grew exponentially, requir-
ing weekly passages (Fig. 1b). The CFU-F assay was used
as a surrogate assay for MSC. In BM total nucleated cell
population, the estimated CFU mean count resulted as 56/
106 TNC. MSC treated with osteogenic medium formed
small deposits of hydroxyapatite intensely red stained with
Alizarin S (Fig. 1c). MSC treated with adipogenic medium
were successfully diVerentiated towards adipogenic lin-
eages: lipid vacuoles started to accumulate in the cyto-
plasm of the cells just after 2–3 days of stimulation and
they were orange–red stained after 21 days (Fig. 1d).
FACS analysis was used to assess the purity of our MSC
and the existence of a homogeneous population of adherent
cells (after 4–5 passages). After the exclusion of dead cells,
(R1 on 7-AAD negative elements) cell population resulted
uniformly positive for CD90, CD44, CD54, CD73, and
CD106. There was no signiWcant contamination of haema-
topoietic cells, as Xow cytometry was negative for markers
of haematopoietic lineage, including CD11b and CD45
(Fig. 1e).
Skin graft survival
The mean skin graft survival and percentage of rats with
rejected or not rejected skin allograft is summarized in
Table 1 and skin graft survival curves are shown in Fig. 2.
The graft from untreated animals (A; n = 13) was
rejected with a mean § standard deviation (SD) of
17 § 1.8 days. Among CsA-treated rats (B; n = 14), 43%
(6/14) did not reject and 57% (8/14) had a mean § SD skin
graft survival of 15 § 3.8 days. The CsA concentration
(5 mg/kg) used for the treatment of the transplanted rats
signiWcantly prolongs skin allograft survival compared to
control animals (B vs. A P < 0.01) but it cannot induce
complete engraftment in all animals. The administration of
MSC in CsA-treated rats increased skin allograft survival in
comparison with untreated animals (C vs. A P < 0.001) as
57% (8/14) rats receiving combined treatment of MSC and
Fig. 1 Characteristics of MSC. 
Cells were enumerated using a 
haemocytometer at each passage 
and reached a cellular expansion 
up to a factor of 109 in 3 months: 
a Growth curve, b typical mor-
phology. DiVerentiation into 
respective lineages was identi-
Wed under speciWc conditions: 
c deposits of hydroxyapatite in-
tensely red stained with Alizarin 
S after culture in osteogenic me-
dium, d orange–red stained lipid 
vacuoles of the cytoplasm of 
MSC treated with adipogenic 
medium. Flow cytometric analy-
sis including CD11b and CD45 
antibodies showed no contami-
nation of haematopoietic cells 
and positivity for classical mes-
enchymal markers CD44, CD54, 
CD73, CD90, CD106 (e)123
120 Arch Dermatol Res (2008) 300:115–124CsA (C, n = 14) had no allograft rejection and 43% (6/14)
rejected the graft with a mean graft survival time of
19 § 3.0 days. Some rats of this group were observed for
2 months and showed no allograft rejection. In contrast, rats
treated with MSC only (D, n = 21) rejected the graft with a
mean § SD skin graft survival of 13 § 1 days, indicating
that donor MSC accelerate graft rejection (D vs. A
P < 0.001). Kaplan–Meier curves (Fig. 2) indicate a detri-
mental eVect of MSC administration on skin allograft sur-
vival in comparison with the other groups. Logrank
analysis showed a signiWcant diVerence among the four
groups (P < 0.001). On the other hand, MSC infusion in
immunosuppressed animals improved skin graft survival in
comparison to the control (C vs. A P < 0.001) as well as
MSC group (C vs. D P < 0.001). Combined treatment
(MSC and CsA) decreased graft rejection compared with
the group treated with CsA only, although the diVerence
was not statistically signiWcant (P = 0.2).
Histological evaluation
Histological analysis of skin biopsies from arm A rats
showed a dense lymphocytic inWltrate in dermis, particu-
larly in peri-follicular areas, with apoptotic keratinocytes,
that is a typical graft rejection pattern (Fig. 3a). InXamma-
tory inWltrate (F) and epidermis thickness (ET) were ana-
lysed. Mean F value was 2.7 while mean ET value was
73.6 m. In arm B, histological qualitative examination of
skin graft showed mild-low dense lymphocytes dermal
inWltrate and signs of re-epithelization in the epidermis. The
graft rejection pattern was less evident and apoptotic kerati-
nocytes were present almost exclusively in the follicular
epithelium (Fig. 3b). Mean F value was 2.2, while mean ET
value was 80.7 m. In Group C, signs of mild-low graft
rejection were evident, with a lichenoid inWltrate in the
upper dermis and apoptotic keratinocytes in the epidermis
(Fig. 3c). Signs of re-epithelization in the epidermis were
also present. Mean F value was 2.2, and mean ET value
was 77.6 m. Group D was qualitatively very heterogeneus
with processes of regeneration (Wbroblastic activation) and
with evident signs of epidermal degeneration and graft
rejection only in some samples (Fig. 3d). In some frag-
ments, the inXammatory inWltrate did not allow a clear eval-
uation of the type of reaction. Mean F value was 2.9 while
mean ET value was 48 m. DiVerences among groups were
not statistically signiWcant.
Histochemical stains were performed to exclude bacte-
rial infections. No bacteria were identiWable in the tissue
sections by Gram and Warthin–Starry stains. Neutrophils
were attracted by the necrotic epidermis.
Cytokine expression analysis
Using a real-time quantitative RT-PCR method, we exam-
ined the mRNA expression of diVerent genes in rat skin
allograft on day 10 after transplantation. Figure 4 summa-
rizes the data of mRNA levels expressed as fold changes in
relation to the control group (untreated). We studied the
expression of pro-inXammatory cytokine genes such as
IFN-, IL-2 and TNF-. IFN- and IL-2 gene expression
were signiWcantly diVerent among the four groups
(P < 0.0001 and P = 0.023, respectively). In particular,
IFN- mRNA levels were signiWcantly lower in CsA group
(4.3-fold, P = 0.004) and MSC group (3.6-fold, P = 0.002)
in comparison with the control group. Moreover,
CsA + MSC group showed signiWcantly higher IFN-
mRNA levels in comparison to CsA and MSC groups
(P = 0.07 and 0.008, respectively). IL-2 mRNA levels
among the four groups showed an expression pattern simi-
lar to that observed for IFN-; the diVerence is statistically
signiWcant both in CsA and MSC groups in comparison
with the untreated group (P = 0.039 and 0.010, respec-
tively). The overall TNF- mRNA levels among the four
groups were statistically diVerent (P = 0.04). TNF-
mRNA gene expression was lower in CsA and in
CsA + MSC groups, where it reached statistical signiW-
cance (P = 0.023) in comparison with the control group.
Analysis of anti-inXammatory molecules such as IL-10
showed no diVerences between MSC and untreated ani-
mals. IL-10 mRNA levels in all groups were not statisti-
cally diVerent. Interestingly, in CsA + MSC group there
Fig. 2 Kaplan–Meier allograft survival curves for rats receiving skin
allograft only (CTRL control, blue line, n = 13), skin allograft and CsA
treatment (CsA, pink line, n = 14), skin allograft, CsA treatment and
donor MSC infusion (MSC + CsA, red line, n = 14), skin allograft and
donor MSC infusion (MSC, azure line, n = 21). Observation period:
30 days. Logrank test showed a signiWcant diVerence among the
groups (P < 0.001)123
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controls (1.6-fold), even if it did not reach statistical signiW-
cance.
TGF- gene is a well-known regulator of a number of
cellular activities including tissue Wbrogenesis, condrogenic
diVerentiation and immunomodulation. The overall diVer-
ence of TGF- mRNA levels among the four groups was
statistically diVerent (P = 0.002). TGF- mRNA levels
were lower in CsA + MSC group than in CsA (P = 0.002),
untreated (P = 0.019) and MSC (P = 0.02) groups.
Discussion
The demonstration of the in vitro immunosuppressive eVect
of MSC raised the issue of whether such property could
also be reproduced in the setting of solid organs transplan-
tation.
In this study we have examined the eVects of MSC intra-
venous administration on skin allograft survival in an in
vivo preclinical rat model. Results obtained from the pres-
ent study showed that treatment with donor MSC without
immunosuppressive therapy reduced the mean skin graft
survival as compared to control animals, suggesting an
immunogenic, rather than a tolerogenic role for these cells.
CsA treatment resulted in graft survival in 43% of animals.
Rats treated with combined therapy (CsA and MSC)
showed a better pattern with 57% of graft survival, suggest-
ing a synergistic eVect of the two treatments, although the
diVerences between the two groups was not statistically sig-
niWcant. The synergistic immunosuppressive eVect of CsA
and MSC for the inhibition of lymphocytes proliferation
was demonstrated in vitro [22].
Accelerated graft rejection upon MSC administration
was also recently demonstrated in a heart transplantation
preclinical model [16]. The authors conWrmed the in vitro
immunomodulatory properties of MSC but do not support
their tolerogenic properties in vivo, as MSC injection were
ineVective in prolonging allograft survival irrespective of
the dose, route of administration and origin (syngeneic or
allogeneic). In addition, the authors reported that the
administration of MSC, together with low dose delayed
CsA administration, accelerates rejection. This discrepancy
with our Wndings may either be due to diVerent dosage and
Fig. 3 a Haematoxylin–eosin £50, b haematoxylin–eosin £200; arm
D (MSC): evident signs of epidermal degeneration and sometimes
ulceration; necrotic apoptotic keratinocytes and neutrophil granulo-
cytes recall are frequent Wndings; a dense lymphocytic inWltrate is pres-
ent in the entire dermis. c Haematoxylin–eosin £100; arm A (control):
epidermis is conserved with lichenoid graft rejection and diVuse mono-
cytic inWltrates in the dermis. d Haematoxylin–eosin £400; particular
of lymphocytic satellitosis. e Haematoxylin–eosin £50, f haematoxy-
lin–eosin £200; arms B (CsA) and C (MSC + CsA) graft rejection pat-
tern is less evident and apoptotic keratinocytes are present almost in the
follicular epitelium, a mild–low dense lymphocytes dermal inWltrate is
present and remnants of the pre-existing epidermis are detectable
above a thickened corneum layer123
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genic properties of the organs. Moreover, our data are in
agreement with another recent study [10] demonstrating
that MHC-mismatched murine MSC led to a robust and
speciWc cellular immune response in non-immunosup-
pressed allogeneic mice.
Results from histological analysis of skin biopsies corre-
lated with skin graft survival data: inXammatory reaction
was more intense in groups A and D which showed a rapid
skin graft rejection. Although the epidermis thickness value
did not reach statistical signiWcance, in CsA-treated animals
(groups B and C) the mean ET value was higher in compar-
ison with the control group (A), indicating a correlation
with reparative phenomena observed in the histopatholo-
gical analysis. On the other hand, the MSC treated group
(D) showed the lowest ET value in comparison to the con-
trol group that was in correlation with intense inXammatory
inWltrate and sometimes with epidermal ulceration.
Our data on cytokines expression analysis at the site of
skin graft showed that CsA treatment signiWcantly
decreased pro-inXammatory cytokines IFN- and IL-2 and
reduced TNF- gene expression. Under our conditions,
CsA treatment did not aVect IL-10 gene expression but the
expression of TGF- was enhanced, in agreement with
studies showing that this cytokine is one of the most potent
mediators of the immunosuppressive eVect of CsA [17].
However, TGF- is a polyfunctional molecule involved in
several biological processes other than immunosuppres-
sion [13, 23, 33] TGF- is a well-known regulator of tis-
sue Wbrogenesis by stimulating Wbroblast proliferation,
promoting collagen synthesis and inhibiting collagen deg-
radation. Our data showed that TGF- expression is down-
regulated in the combined treatment rat group C, where the
Wbrotic process seems less intense and there are signs of
skin regeneration. In addition, cytokine gene expression
proWle results from a complex network of reactions. All
investigated cytokines are synthesized, with peculiar tim-
ing, by diVerent cell types present at skin graft biopsies
sites and they play a pivotal role in several important
processes including angiogenesis, Wbrosis inXammatory
Fig. 4 mRNA expression of 
IFN-, IL-2, TNF-, IL-10, 
and TGF- genes. Data are 
expressed as fold changes in 
relation to the control group 
(untreated). Statistically signiW-
cant diVerences among groups 
are reported above the columns123
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cannot correlate the cytokine proWle with histological
examination between graft rejecting and graft accepting
rats, as all rats used for these analyses were sacriWced at
day 10 post transplantation.
Results obtained from gene expression analysis sug-
gested a role of cytokine environment in determining the
MSC eVect on the outcome of solid organ transplantation.
In CsA-treated rats, where the level of pro-inXammatory
cytokines (TNF-, IFN-) is lower than controls, MSC
administration resulted in longer skin graft survival. This
pattern is reverted when the MSC are administered in not
immunosuppressed rats, where the level of the pro-inXam-
matory cytokine TNF- is higher. This hypothesis is
supported by a recent work demonstrating reversal of
immunosuppressive properties of allogeneic MSC possibly
mediated by TNF- in vitro [8]. However, further investi-
gation at systemic level is necessary. The Wnding that a
high level of inXammation may overcome the immunosup-
pressive properties of MSC has also been observed in vivo
in a preclinical model of allogeneic BM transplantation
[36]. In this experimental setting, MSC treatment fails to
prevent GvHD.
In our study, mRNA levels of the two pro-inXammatory
cytokines, IFN- and IL-2, were increased in the combined
(MSC + CsA) group with a better skin graft survival.
Recently, cardiac tolerated grafts have been demonstrated
to have a T cell and macrophage inWltrate with increased
mRNA for Th1 cytokines, IL-2, and IFN- but not Th2
cytokines [30]. Moreover, in other preclinical models, gene
expression of pro-inXammatory cytokines was observed in
tolerated allograft [15].
Despite the large amount of data on the immunosuppres-
sive properties of MSC in vitro [18], only few reports sug-
gest that these immunomodulatory properties of allogeneic
MSC may be translated to the in vivo setting, as little is
known regarding host immune response to MSC. Discor-
dant data are available in vivo on the use of syngeneic and
allogeneic MSC in immunosuppressed or non-immunosup-
pressed animals [10, 14, 16, 27, 34, 36]. Varying results are
probably due to diVerent experimental animal models used,
the diVerent MSC source (human, rat, mouse) and to the
diVerent route of MSC administration (intravenously, in
situ implant). In addition, controversy exists on the immu-
nogenicity and immunomodulating potential of MSC in
vivo. Few animal studies in vivo and in vitro reported that
allogeneic/xenogenic MSC are rejected in an immuno-com-
petent host [14, 16]. Recently Nauta et al. [27] demon-
strated that allogeneic murine MSC are not intrinsically
immunoprivileged as they can induce a memory T cell
response in vivo resulting in graft rejection in a murine
allogeneic BM transplantation model through a cellular
immune response.
In conclusion, our study in a skin allograft transplanta-
tion model demonstrated a clear immunogenic role for
donor (allogeneic) MSC as, when administered in immuno-
competent rats, they stimulate graft rejection. It may be
speculated that immunosuppressive eVect of MSC can be
fully elicited when the survival of these cells is prolonged
by the simultaneous administration of CsA.
The reduction of immunosuppressive drug toxicity and
side eVects is an important goal in solid organ transplanta-
tion but further in-depth studies are necessary to demon-
strate the eYcacy of MSC treatment in immunosuppressed
animals and to reach a clear deWnition of MSC therapeutic
potential.
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